Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AtriCure, Inc.ATRC · Entity 2704 | Director | May 18, 2026 | May 20, 2026 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | EVP, Corporate Affairs & GC | November 12, 2025 | November 14, 2025 |
| Organon & Co.OGN · Entity 4115 | EVP GC & Corporate Secretary | May 04, 2022 | May 06, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AtriCure, Inc.
Report date May 18, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,328 |
Reported balance
After 2026-05-18 transaction · row 1
1 source rowRow 1 · 2026-05-18 · Grant · Acquired 6,144 · Balance 28,328 F1: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.
GILEAD SCIENCES, INC.
Report date November 12, 2025 · Filed November 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,676 |
Ending reported balance
After 2025-11-12 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2025-11-12 · Exercise / conversion · Acquired 17,181 · Balance 60,857 F1: The transactions reported in the Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. Row 2 · 2025-11-12 · Sale · Disposed 17,181 · Balance 43,676 F1: The transactions reported in the Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. Row 3 · 2025-11-12 · Exercise / conversion · Acquired 35,965 · Balance 79,641 F1: The transactions reported in the Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. Row 4 · 2025-11-12 · Sale · Disposed 35,965 · Balance 43,676 F1: The transactions reported in the Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F2: Sales prices for the transactions reported here range from $121.87 to $122.83. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Row 5 · 2025-11-12 · Exercise / conversion · Acquired 500 · Balance 44,176 F1: The transactions reported in the Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. Row 6 · 2025-11-12 · Sale · Disposed 500 · Balance 43,676 F1: The transactions reported in the Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F3: Sales prices for the transactions reported here range from $122.88 to $122.92. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.12 · Expires 2034-03-10 | Direct | 37,799 |
Reported balance
After 2025-11-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-11-12 · Exercise / conversion · Disposed 17,181 · Balance 37,799 F1: The transactions reported in the Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F4: The stock options have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.75 · Expires 2032-07-25 | Direct | 12,655 |
Reported balance
After 2025-11-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-11-12 · Exercise / conversion · Disposed 35,965 · Balance 12,655 F1: The transactions reported in the Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F4: The stock options have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.75 · Expires 2032-07-25 | Direct | 12,155 |
Reported balance
After 2025-11-12 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-11-12 · Exercise / conversion · Disposed 500 · Balance 12,155 F1: The transactions reported in the Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F4: The stock options have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in the Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.
F2: Sales prices for the transactions reported here range from $121.87 to $122.83. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
F3: Sales prices for the transactions reported here range from $122.88 to $122.92. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
F4: The stock options have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.
Organon & Co.
Report date May 04, 2022 · Filed May 06, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,688 |
Ending reported balance
After 2022-05-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-05-04 · Exercise / conversion · Acquired 4,431 · Balance 8,987 F1: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. Row 2 · 2022-05-04 · Tax withholding · Disposed 1,299 · Balance 7,688 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2024-05-04 | Direct | 4,431 |
Reported balance
After 2022-05-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-05-04 · Exercise / conversion · Disposed 4,431 · Balance 4,431 F1: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2: The amount of the RSUs has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F3: On May 4, 2022, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on May 4, 2023 and May 4, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU.
F2: The amount of the RSUs has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations.
F3: On May 4, 2022, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on May 4, 2023 and May 4, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2026 Filed May 20, 2026 16:33 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 6,144 | $0.00 | $0.00 |
DisclosureSEC source: 0001860008-26-000002 · wk-form4_1779294824.xml · nonDerivative · entry 1 Telman Deborah H · CIK 0001860008 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,328 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 00:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 500 | $0.00 Strike: $60.75 | $0.00 |
DisclosureSEC source: 0001860008-25-000009 · wk-form4_1763080568.xml · derivative · entry 9 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,155 Underlying: Common Stock · 500 shares Expires 2032-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in the Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F4 · derivative.exercise_date: The stock options have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 00:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 35,965 | $0.00 Strike: $60.75 | $0.00 |
DisclosureSEC source: 0001860008-25-000009 · wk-form4_1763080568.xml · derivative · entry 8 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,655 Underlying: Common Stock · 35,965 shares Expires 2032-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in the Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F4 · derivative.exercise_date: The stock options have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 00:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 17,181 | $0.00 Strike: $75.12 | $0.00 |
DisclosureSEC source: 0001860008-25-000009 · wk-form4_1763080568.xml · derivative · entry 7 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,799 Underlying: Common Stock · 17,181 shares Expires 2034-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in the Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F4 · derivative.exercise_date: The stock options have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 00:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $122.90 | $61,452.00 |
DisclosureSEC source: 0001860008-25-000009 · wk-form4_1763080568.xml · nonDerivative · entry 6 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,676 F1 · kind: The transactions reported in the Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F3 · price: Sales prices for the transactions reported here range from $122.88 to $122.92. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 00:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 500 | $60.75 | $30,375.00 |
DisclosureSEC source: 0001860008-25-000009 · wk-form4_1763080568.xml · nonDerivative · entry 5 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in the Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 00:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 35,965 | $122.30 | $4,398,591.43 |
DisclosureSEC source: 0001860008-25-000009 · wk-form4_1763080568.xml · nonDerivative · entry 4 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,676 F1 · kind: The transactions reported in the Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F2 · price: Sales prices for the transactions reported here range from $121.87 to $122.83. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 00:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 35,965 | $60.75 | $2,184,873.75 |
DisclosureSEC source: 0001860008-25-000009 · wk-form4_1763080568.xml · nonDerivative · entry 3 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,641 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in the Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 00:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 17,181 | $124.00 | $2,130,444.00 |
DisclosureSEC source: 0001860008-25-000009 · wk-form4_1763080568.xml · nonDerivative · entry 2 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,676 F1 · kind: The transactions reported in the Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 00:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 17,181 | $75.12 | $1,290,636.72 |
DisclosureSEC source: 0001860008-25-000009 · wk-form4_1763080568.xml · nonDerivative · entry 1 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,857 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in the Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. Read SEC document |
| October 25, 2025 Filed Oct 27, 2025 23:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 515 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001860008-25-000007 · wk-form4_1761608628.xml · derivative · entry 3 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,816 Underlying: Common Stock · 515 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| October 25, 2025 Filed Oct 27, 2025 23:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 241 | $120.94 | $29,146.54 |
DisclosureSEC source: 0001860008-25-000007 · wk-form4_1761608628.xml · nonDerivative · entry 2 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,676 Read SEC document |
| October 25, 2025 Filed Oct 27, 2025 23:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 515 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001860008-25-000007 · wk-form4_1761608628.xml · nonDerivative · entry 1 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 10, 2025 Filed Sep 11, 2025 23:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,315 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001860008-25-000005 · wk-form4_1757633494.xml · derivative · entry 3 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,331 Underlying: Common Stock · 1,315 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2025 Filed Sep 11, 2025 23:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 634 | $115.25 | $73,068.50 |
DisclosureSEC source: 0001860008-25-000005 · wk-form4_1757633494.xml · nonDerivative · entry 2 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,402 Read SEC document |
| September 10, 2025 Filed Sep 11, 2025 23:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,315 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001860008-25-000005 · wk-form4_1757633494.xml · nonDerivative · entry 1 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| July 25, 2025 Filed Jul 28, 2025 21:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 8,229 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-019654 · form4.xml · derivative · entry 5 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,646 Underlying: Common Stock · 8,229 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a three-year vesting schedule. 33.33% will vest on each yearly anniversary of the date of the grant until fully vested. F3 · derivative.expiration_date: The restricted stock units have a three-year vesting schedule. 33.33% will vest on each yearly anniversary of the date of the grant until fully vested. Read SEC document |
| July 25, 2025 Filed Jul 28, 2025 21:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 514 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-019654 · form4.xml · derivative · entry 4 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,875 Underlying: Common Stock · 514 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| July 25, 2025 Filed Jul 28, 2025 21:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 3,823 | $116.20 | $444,232.60 |
DisclosureSEC source: 0001127602-25-019654 · form4.xml · nonDerivative · entry 3 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,721 Read SEC document |
| July 25, 2025 Filed Jul 28, 2025 21:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 8,229 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-019654 · form4.xml · nonDerivative · entry 2 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| July 25, 2025 Filed Jul 28, 2025 21:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 514 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-019654 · form4.xml · nonDerivative · entry 1 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 23:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,313 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-017337 · form4.xml · derivative · entry 3 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,389 Underlying: Common Stock · 1,313 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 23:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 430 | $110.09 | $47,338.70 |
DisclosureSEC source: 0001127602-25-017337 · form4.xml · nonDerivative · entry 2 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,801 Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 23:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,313 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-017337 · form4.xml · nonDerivative · entry 1 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 19, 2025 Filed May 21, 2025 20:41 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 5,401 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-25-000059 · wk-form4_1747860104.xml · nonDerivative · entry 1 Telman Deborah H · CIK 0001860008 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,184 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| April 25, 2025 Filed Apr 28, 2025 17:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 514 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-012668 · form4.xml · derivative · entry 3 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,702 Underlying: Common Stock · 514 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| April 25, 2025 Filed Apr 28, 2025 17:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 158 | $103.17 | $16,300.86 |
DisclosureSEC source: 0001127602-25-012668 · form4.xml · nonDerivative · entry 2 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,918 Read SEC document |
| April 25, 2025 Filed Apr 28, 2025 17:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 514 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-012668 · form4.xml · nonDerivative · entry 1 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,076 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 23:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 7,680 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-009290 · form4.xml · derivative · entry 5 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,216 Underlying: Common Stock · 7,680 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 23:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 33,940 | $0.00 Strike: $117.21 | $0.00 |
DisclosureSEC source: 0001127602-25-009290 · form4.xml · derivative · entry 4 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,940 Underlying: Common Stock · 33,940 shares Expires 2035-03-10 F4 · derivative.exercise_date: The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 23:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 3,343 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-009290 · form4.xml · derivative · entry 3 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,356 Underlying: Common Stock · 3,343 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 23:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,130 | $117.21 | $132,447.30 |
DisclosureSEC source: 0001127602-25-009290 · form4.xml · nonDerivative · entry 2 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,562 F2 · balance_after: Balance adjusted to reflect shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 23:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,343 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-009290 · form4.xml · nonDerivative · entry 1 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 21:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 12,371 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003389 · form4.xml · nonDerivative · entry 1 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,011 F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting person on March 10, 2023 and March 10,2024. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of the performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting person until the requisite continuing service requirements are met. Read SEC document |
| January 25, 2025 Filed Jan 27, 2025 22:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 515 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-002030 · form4.xml · derivative · entry 3 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,879 Underlying: Common Stock · 515 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 25, 2025 Filed Jan 27, 2025 22:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 187 | $93.07 | $17,404.09 |
DisclosureSEC source: 0001127602-25-002030 · form4.xml · nonDerivative · entry 2 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,640 Read SEC document |
| January 25, 2025 Filed Jan 27, 2025 22:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 515 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-002030 · form4.xml · nonDerivative · entry 1 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 00:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 639 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-029181 · form4.xml · derivative · entry 3 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,394 Underlying: Common Stock · 639 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 00:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 306 | $92.34 | $28,256.04 |
DisclosureSEC source: 0001127602-24-029181 · form4.xml · nonDerivative · entry 2 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,312 Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 00:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 639 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-029181 · form4.xml · nonDerivative · entry 1 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| October 25, 2024 Filed Oct 28, 2024 19:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 514 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-026017 · form4.xml · derivative · entry 3 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,033 Underlying: Common Stock · 514 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| October 25, 2024 Filed Oct 28, 2024 19:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 242 | $89.00 | $21,538.00 |
DisclosureSEC source: 0001127602-24-026017 · form4.xml · nonDerivative · entry 2 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,979 Read SEC document |
| October 25, 2024 Filed Oct 28, 2024 19:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 514 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-026017 · form4.xml · nonDerivative · entry 1 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,221 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 639 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023825 · form4.xml · derivative · entry 3 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,547 Underlying: Common Stock · 639 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 307 | $81.44 | $25,002.08 |
DisclosureSEC source: 0001127602-24-023825 · form4.xml · nonDerivative · entry 2 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,707 Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 639 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023825 · form4.xml · nonDerivative · entry 1 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 21:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 8,230 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-021048 · form4.xml · derivative · entry 5 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,186 Underlying: Common Stock · 8,230 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of the grant until fully vested. F3 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of the grant until fully vested. Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 21:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 514 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-021048 · form4.xml · derivative · entry 4 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,416 Underlying: Common Stock · 514 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 21:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 8,230 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-021048 · form4.xml · nonDerivative · entry 3 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 21:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 514 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-021048 · form4.xml · nonDerivative · entry 2 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.